(Q38111308)

29 August 2017

Current and future treatments for Behçet's uveitis: road to remission (English)

1 reference

29 August 2017

0 references

1 reference

Marina Mesquida

1

0 references

María Victoria Hernández

object named as

María Victoria Hernández

4

0 references

Alfredo Adán

object named as

Alfredo Adán

7

0 references

Gerard Espinosa

5

object named as

Gerard Espinosa

1 reference

29 August 2017

Blanca Molins

2

1 reference

29 August 2017

Victor Llorenç

3

1 reference

29 August 2017

Andrew D Dick

6

1 reference

29 August 2017

language of work or name

1 reference

1 June 2013

1 reference

International Ophthalmology

29 August 2017

1 reference

29 August 2017

34

1 reference

29 August 2017

2

1 reference

29 August 2017

365-381

1 reference

https://scigraph.springernature.com/pub.10.1007/s10792-013-9788-5

29 August 2017

0 references

cites work

Behçet's disease: ocular effects and treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Epidemiology of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Prevalence of Behçet's disease in Istanbul, Turkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Etiopathogenesis of Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Light on the horizont: biologicals in Behçet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Behcet's disease: from East to West.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Clinical features of chinese patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Ocular features of Behcet's disease: an international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Behçet uveitis in the American midwest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Cyclosporin A in the treatment of severe Behçet's uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Calcineurin inhibitors in renal transplantation: what is the best option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

A controlled trial of azathioprine in Behçet's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Azathioprine in severe uveitis of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Interferon-alpha in the management of patients with Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Intraocular cytokine environment in active Behçet uveitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Clinical pharmacokinetics of TNF antagonists: how do they differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Adalimumab for sight-threatening uveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Behçet's disease as an autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Resistant Behçet disease responsive to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Treatment of retinal vasculitis in Behçet's disease with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

The use of biologic agents in the treatment of ocular manifestations of Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Effects of infliximab in the treatment of refractory posterior uveitis of Behçet’s disease after withdrawal of infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Cytokines and Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10792-013-9788-5

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

21 January 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis

1 reference

12 December 2020

Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders.

1 reference

12 December 2020

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

1 reference

12 December 2020

Behçet disease: visual prognosis and factors influencing the development of visual loss

1 reference

12 December 2020

Successful use of canakinumab in a patient with resistant Behçet's disease

1 reference

12 December 2020

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

12 December 2020

Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)

1 reference

12 December 2020

Steroid sensitivity and postoperative course of seven patients with Behçet's disease

1 reference

12 December 2020

Treatment of Adamantiades-Behçet disease with systemic interferon alfa

1 reference

12 December 2020

Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease

1 reference

12 December 2020

Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab

1 reference

12 December 2020

Cytokine profile in Behçet's disease patients. Relationship with disease activity

1 reference

12 December 2020

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab

1 reference

12 December 2020

Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome

1 reference

12 December 2020

One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β

1 reference

12 December 2020

Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

1 reference

12 December 2020

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease

1 reference

12 December 2020

Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina

1 reference

12 December 2020

Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation

1 reference

12 December 2020

Rituximab for uveitis

1 reference

12 December 2020

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study

1 reference

12 December 2020

Therapy: Behçet uveitis: good results for IFN-alpha-2a

1 reference

12 December 2020

Golimumab for uveitis

1 reference

12 December 2020

Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN

1 reference

12 December 2020

Influence of human recombinant interferon- 2a (rhIFN- 2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

1 reference

12 December 2020

Induction of regulatory T cells by infliximab in Behcet's disease

1 reference

12 December 2020

10.1007/S10792-013-9788-5

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference